BlossomHill Therapeutics, Inc. (BLSM)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
14.98 USD
-0.28
(-1.835%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:30 a.m. EDT
The immediate outlook is bearish due to a sharp, accelerating price collapse over the last two weeks, dropping from $25.25 to $17.48, which suggests strong selling pressure and a breakdown of the recent support structure. While the balance sheet currently appears robust with a current ratio of 5.42 and manageable debt relative to cash, the business fundamentals are severely compromised by negative earnings, negative book value, and a forward P/E that indicates no expected profitability. The lack of any price history prevents assessing a long-term trend, but the current financial reality—burning cash with no earnings and a negative equity base—makes the investment case untenable for holding. Furthermore, there is no dividend income to offset the capital loss, leaving investors exposed entirely to the risk of further dilution or total value erosion as the company attempts to fund its operations. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 28.486 |
| Market Cap | 476,137,920 |
| Forward P/E | -3.79 |
| Website | https://bhtherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.046249986 |
| Address1 | 10,255 Science Center Drive |
| Address2 | Suite 200 |
| All Time High | 27.99 |
| All Time Low | 14.7 |
| Ask | 15.32 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 170,150 |
| Average Daily Volume3 Month | 250,118 |
| Average Volume | 250,118 |
| Average Volume10Days | 170,150 |
| Bid | 16.03 |
| Bid Size | 1 |
| Book Value | -63.147 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.98 |
| Current Ratio | 5.422 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 15.5299 |
| Day Low | 14.7 |
| Debt To Equity | 28.486 |
| Display Name | BlossomHill Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,789,734,600 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -84,740,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.8 |
| Enterprise Value | 660,955,968 |
| Eps Current Year | -5.09502 |
| Eps Forward | -3.95471 |
| Eps Trailing Twelve Months | -4.65 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.365625 |
| Fifty Day Average Change | -4.385626 |
| Fifty Day Average Change Percent | -0.22646445 |
| Fifty Two Week Change Percent | -4.6249986 |
| Fifty Two Week High | 27.99 |
| Fifty Two Week High Change | -13.01 |
| Fifty Two Week High Change Percent | -0.46480888 |
| Fifty Two Week Low | 14.7 |
| Fifty Two Week Low Change | 0.27999973 |
| Fifty Two Week Low Change Percent | 0.019047601 |
| Fifty Two Week Range | 14.7 - 27.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,786,109,400,000 |
| Float Shares | 17,744,879 |
| Forward Eps | -3.95471 |
| Forward P E | -3.7878883 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 69 |
| Fullday Change | -0.2800007 |
| Fullday Change Percent | -1.8348669 |
| Fullday Price | 14.98 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12707 |
| Held Percent Institutions | 0.30745 |
| Implied Shares Outstanding | 31,784,909 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-08-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California. |
| Long Name | BlossomHill Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 476,137,920 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_700852009 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -81,599,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 710,074,867 |
| Number Of Analyst Opinions | 5 |
| Open | 15.17 |
| Operating Cashflow | -70,978,000 |
| Operating Margins | 0.0 |
| Phone | (858) 732-3880 |
| Previous Close | 15.26 |
| Price Eps Current Year | -2.940126 |
| Price Hint | 2 |
| Price To Book | -0.23722425 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.122 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.280001 |
| Regular Market Change Percent | -1.83487 |
| Regular Market Day High | 15.5299 |
| Regular Market Day Low | 14.7 |
| Regular Market Day Range | 14.7 - 15.5299 |
| Regular Market Open | 15.17 |
| Regular Market Previous Close | 15.26 |
| Regular Market Price | 14.98 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 176,511 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 31,784,909 |
| Shares Percent Shares Out | 0.0149 |
| Shares Short | 473,807 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 110,782 |
| Short Name | BlossomHill Therapeutics, Inc. |
| Short Ratio | 2.11 |
| Source Interval | 15 |
| State | CA |
| Symbol | BLSM |
| Target High Price | 40.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 35.4 |
| Target Median Price | 35.0 |
| Total Cash | 95,376,000 |
| Total Cash Per Share | 3.001 |
| Total Debt | 23,371,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.365625 |
| Two Hundred Day Average Change | -4.385626 |
| Two Hundred Day Average Change Percent | -0.22646445 |
| Type Disp | Equity |
| Volume | 176,511 |
| Website | https://bhtherapeutics.com |
| Zip | 92,121 |